At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
Gemcitabine +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gemcitabine and High-dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Vinorelbine, and 4 other interventions for Hodgkin Disease and 2 related conditions. Completed, enrolled 146 participants across 1 site.
Detailed Summary
This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease, Hodgkin's Lymphoma, Lymphoma
CountriesUnited States
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2001
First PostedOct 2006
Primary CompletionMar 2008
Study CompletionSep 2010
TodayJul 2026
First PostedOct 16, 2006
Enrollment StartSep 1, 2001
Primary CompletionMar 1, 2008
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 19.7 years ago
Interventions
Gemcitabinedrug
Vinorelbinedrug
Carmustinedrug
Etoposidedrug
Cyclophosphamidedrug
Autologous HCTprocedure